| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Age-Related Macular Degeneration | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Choroidal Neovascularization | |||||
| Macular Degeneration | |||||
| 3 | More general conditions related to this trial | ||||
| Choroid Diseases | |||||
| Eye Diseases | |||||
| Metaplasia | |||||
| Neovascularization, Pathologic | |||||
| Pathologic Processes | |||||
| Retinal Degeneration | |||||
| Retinal Diseases | |||||
| Uveal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Verteporfin for injection | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Verteporfin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Dermatologic Agents | |||||
| Pharmacologic Actions | |||||
| Photosensitizing Agents | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Novartis | |||||
| QLT Inc | |||||
|
